IVRA (Melphalan Hydrochloride) Patent Expiration, LOE Window & CMS Spending

IVRA (Melphalan Hydrochloride) by Apotex: FDA Orange Book core substance LOE 2036-06-29, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $5,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayN217110 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-06-29
Last Listed Patent or Exclusivity Date2036-06-29
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,500 intro WAC)